Feed Category: MedDiagnostics

FRIENDSWOOD, Texas, February 07, 2023–(BUSINESS WIRE)–Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it… [Read More]

In this piece, we will take a look at the 15 worst stock picks of Cathie Wood in 2022. For her top five worst stock… [Read More]

Genetic Technologies LtdMELBOURNE, Australia, Feb. 07, 2023 (GLOBE NEWSWIRE) — Genetic Technologies Limited (ASX:GTG; NASDAQ:GENE, “Company”, “GTG”, or “Genetic Technologies”), a global leader in guideline-driven… [Read More]

ENGLEWOOD, CO / ACCESSWIRE / February 7, 2023 / Aytu BioPharma, Inc. (the Company or “Aytu”) (NASDAQ:AYTU), a commercial stage pharmaceutical and consumer health company… [Read More]

BioSig Technologies, Inc.Westport, CT, Feb. 07, 2023 (GLOBE NEWSWIRE) –Chief Financial Officer Steve Chaussy retires following 12 years of serviceSteve Buhaly joins BioSig as CFOBuhaly… [Read More]

Myriad Genetics, Inc.SALT LAKE CITY, Feb. 07, 2023 (GLOBE NEWSWIRE) — Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, highlighted… [Read More]

OraSure Technologies, Inc.BETHLEHEM, Pa., Feb. 07, 2023 (GLOBE NEWSWIRE) — OraSure Technologies, Inc. (NASDAQ: OSUR) has scheduled its regular earnings conference call covering 2022 fourth… [Read More]

Usually, when one insider buys stock, it might not be a monumental event. But when multiple insiders are buying like they did in the case… [Read More]

SOUTH SAN FRANCISCO, Calif., February 06, 2023–(BUSINESS WIRE)–Veracyte, Inc. (Nasdaq: VCYT) announced today that it will release financial results for the fourth quarter and full-year… [Read More]

T2 Biosystems, Inc.LEXINGTON, Mass., Feb. 06, 2023 (GLOBE NEWSWIRE) — T2 Biosystems, Inc. (NASDAQ:TTOO) a leader in the rapid detection of sepsis-causing pathogens and antibiotic… [Read More]

FREMONT, Calif., February 06, 2023–(BUSINESS WIRE)–Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today that its management team will participate at… [Read More]

Needham has upgraded Personalis Inc (NASDAQ: PSNL) to Buy from Hold with a price target of $8.The analyst writes that Personalis’s cash burn has likely peaked and expects it… [Read More]